UK markets close in 4 hours 1 minute
  • FTSE 100

    7,878.06
    +41.35 (+0.53%)
     
  • FTSE 250

    20,305.37
    -104.01 (-0.51%)
     
  • AIM

    880.97
    -2.82 (-0.32%)
     
  • GBP/EUR

    1.1197
    -0.0009 (-0.08%)
     
  • GBP/USD

    1.1996
    -0.0028 (-0.23%)
     
  • BTC-GBP

    19,179.22
    +36.94 (+0.19%)
     
  • CMC Crypto 200

    528.74
    +3.60 (+0.69%)
     
  • S&P 500

    4,111.08
    -25.40 (-0.61%)
     
  • DOW

    33,891.02
    -34.99 (-0.10%)
     
  • CRUDE OIL

    75.31
    +1.20 (+1.62%)
     
  • GOLD FUTURES

    1,882.90
    +3.40 (+0.18%)
     
  • NIKKEI 225

    27,685.47
    -8.18 (-0.03%)
     
  • HANG SENG

    21,298.70
    +76.54 (+0.36%)
     
  • DAX

    15,330.35
    -15.56 (-0.10%)
     
  • CAC 40

    7,142.10
    +5.00 (+0.07%)
     

Novo Nordisk A/S – Share repurchase programme

Novo Nordisk A/S
Novo Nordisk A/S

Bagsværd, Denmark, 23 January 2023 – On 4 November 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022.

Under the programme initiated 4 November 2022, Novo Nordisk will repurchase B shares for an amount up to DKK 3.8 billion in the period from 7 November 2022 to 30 January 2023.

Since the announcement of the programme, the following transactions have been made:

 

Number of
B shares

Average
purchase price

Transaction
value, DKK

Accumulated, last announcement

3,439,265

 

3,046,124,188

16 January 2023

75,000

953.10

71,482,811

17 January 2023

75,000

958.73

71,905,115

18 January 2023

75,000

959.10

71,932,215

19 January 2023

75,000

963.27

72,245,468

20 January 2023

75,000

964.91

72,368,320

Accumulated under the programme

3,814,265

 

3,406,058,116

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 31,243,083 B shares of DKK 0.20 as treasury shares, corresponding to 1.4% of the share capital. The total amount of A and B shares in the company is 2,280,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 24 billion during a 12-month period beginning 2 February 2022. As of 20 January 2023, Novo Nordisk has since 2 February 2022 repurchased a total of 29,553,897 B shares at an average share price of DKK 798.18 per B share equal to a transaction value of DKK 23,589,460,171.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 53,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube.

Contact for further information

Media:

 

Ambre Brown Morley
+45 3079 9289
abmo@novonordisk.com

Natalia Salomao Abrahao (US)
+1 848 304 1027
niaa@novonordisk.com

Investors:

 

Daniel Muusmann Bohsen
+45 3075 2175
dabo@novonordisk.com

Jacob Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com

David Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com

Mark Joseph Root (US)
+1 848 213 3219
mjhr@novonordisk.com

Company announcement No 03 / 2023

Attachments